Find trending articles through Social News Discovery®! Providing a collaboration of news through social media technologies.
Follow your friends and create your own Online Social Newspaper! Invite your friends to follow you from Facebook. Filter the news articles you see by section, clipper, or mood. Rate each article and comment on all news clips!
Receive site and email notifications about comments and news clips that you are collaborating on!
Get the latest news on the Everyone page, the viral and trending news clips will always be at the top! See the trending news and articles!
"NEW ORLEANS--Merck & Co. and Samsung Bioepis won’t be the first to roll out a biosimilar version of Sanofi’s multibillion-dollar basal insulin, Lantus. But they aim to step up the competition when they do--and new data unveiled Monday back their case for approval.", www.fiercepharma.com
"NEW ORLEANS--Diabetes researchers, endocrinologists and primary care docs, patient advocacy groups and, of course, media descended on this city over the weekend to catch the latest data on the disease, and FiercePharma found plenty of news on drugs worth watching. Here’s our selection.", www.fiercepharma.com
"Sanofi ((SNYNF, SNY) announced the presentation of the results of the pivotal Phase 3 LixiLan-O and LixiLan-L clinical trials with the investigational titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide in adults with type 2 diabetes.", www.rttnews.com
"EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.", www.econotimes.com
"Type 2 diabetes patients treated with iGlarLixi (formerly LixiLan) had significantly greater reductions in blood glucose (HbA1c) versus treatment with either lixisenatide or Lantus® Treatment with iGlarLixi also resulted in body weight re", www.pharmiweb.com
"NEW ORLEANS—As Sanofi’s top-selling Lantus careens toward its first U.S. biosimilar competition in December, the French drugmaker has not only been developing a follow-up diabetes product — the longer-acting Toujeo, FDA-approved last year — but a combination therapy that pairs Lantus with its GLP-1 drug Lyxumia.", www.fiercepharma.com
Please enjoy the site during our beta phase and provide us with feedback on suggestions and issue details. Please remember that we are still in beta and there will be issues and site changes during this time.
Newsclip® the leading Online Social Newspaper, find trending articles through Social News Discovery®!
You can reopen the "Getting Started Tutorial" dialog from within the About menu in the top right corner.